

Stevia rebaudiana Bertoni:

A Natural Alternative for Treating Diseases Associated with Metabolic Syndrome

Areli Carrera-Lanestosa,¹ Yolanda Moguel-Ordóñez,² and Maira Segura-Campos¹¹Faculty of Chemical Engineering, Autonomous University of Yucatan, Merida, Mexico.²National Institute for Forest, Agronomic, and Livestock Research, Mococho Experimental Field, Yucatan, Mexico.

ABSTRACT *Stevia rebaudiana* (SR) is often used by the food industry due to its steviol glycoside content, which is a suitable calorie-free sweetener. Further, both *in vitro* and *in vivo* studies indicate that these glycosides and the extracts from SR have pharmacological and therapeutic properties, including antioxidant, antimicrobial, antihypertensive, antidiabetic, and anticancer. This work reviews the antiobesity, antihyperglycemic, antihypertensive, and antihyperlipidemic effects of the majority of glycosides and aqueous/alcoholic extracts from the leaves, flowers, and roots of the SR. These compounds can serve as a natural and alternative treatment for diseases that are associated with metabolic syndrome, thus contributing to health promotion.

KEYWORDS: diabetes • dyslipidemia • hypertension • metabolic syndrome • obesity • *Stevia rebaudiana*

INTRODUCTION

METABOLIC SYNDROME is a set of cardiometabolic factors that have insulin resistance (IR) and oxidative stress, leading to an increase in the risk of suffering cardiovascular diseases. These factors include abdominal obesity (AO), arterial hypertension (AHT), diabetes mellitus (DM), inflammation, hepatic steatosis, and dyslipidemia. Further, people with metabolic syndrome have a constant risk of getting cerebrovascular disease (CVD) and ischemic cardiomyopathy in the short term.^{1,2}

Cardiovascular disease is the first cause of morbidity and mortality in Mexico, where endocrines diseases such as AO, DM, and AHT, along with an abnormal lipid metabolism, are risk factors for CVD. Moreover, CVD is currently among the first 10 causes of death worldwide.^{3,4} Currently, there are several chemically synthesized pharmaceuticals for treating these diseases. However, many of them have secondary undesirable effects such as lactic acidosis, metallic taste, and vitamin B₁₂ deficiency. Therefore, there is a demand for new natural-based medicinal compounds,^{4,5} with *Stevia rebaudiana* (SR) Bertoni being a potential source for these compounds.

SR is native to the Amambay Mountains, which are located between southern Brazil and northern Paraguay. Guaraní Indians live there and since ancient times have consumed SR as a sweetener and a medicinal plant that they call *ka'a he'ë* or sweet herb.⁶ The presence of steviol gly-

cosides in SR is responsible for its sweet taste. These compounds are 200–300 times sweeter than saccharose-based candies and get advantage for not containing calories.⁷ Besides containing natural sweeteners, SR has also a complex mixture of other compounds, including terpenes, tannins, sterols, volatile acids, vitamins, carotenes, flavonoids, enzymes, organic acids, polysaccharides, hormones, and microelements.⁸ Further, interesting biofunctional properties have been found in phytochemicals that are present in SR, which encourages the study of its properties. Thus, this work aims at reviewing the antiobesity, antihyperglycemic, antihypertensive, and antihyperlipidemic effects of the majority glycosides and aqueous/alcoholic extracts from the leaves, flowers, and roots of SR. These glycosides and extracts can serve as a natural and alternative treatment for the diseases that are associated with metabolic syndrome.

METABOLIC SYNDROME

Metabolic syndrome is a set of risk factors that are characterized by the presence of AO, high arterial pressure (AP), and disorder in the carbohydrate and lipid metabolism. Under AO, the functionality of adipose tissues (AT) decreases, causing a misbalance of reactive oxygen species and proinflammatory cytokines such as tumor necrosis factor- α (TNF- α), interleukin 6 (IL-6), adiponectin, leptin, and plasminogen activator inhibitor (PAI1). This systematically triggers inflammatory processes that will eventually increase the risk of developing cardiovascular diseases (Fig. 1).^{1,2,9–11} Metabolic syndrome has other names, including IR syndrome, plurimetabolic syndrome, and deadly quartet. However, in 1998, the World Health Organization

Manuscript received 26 November 2016. Revision accepted 26 April 2017.

Address correspondence to: Maira Segura-Campos, PhD, Facultad de Ingeniería Química, Universidad Autónoma de Yucatán, Periférico Norte, Km. 33.5, Tablaje catastral 13615, Col. Chuburná de Hidalgo Inn, Mérida CP. 97203, Yucatán, México, E-mail: maira.segura@correo.uady.mx




FIG. 1. General mechanism of the development of metabolic syndrome. IL-6, interleukin-6; LDL, lipoprotein low density; ROS, reactive oxygen species; TNF- α , tumor necrosis factor- α ; VLDL, very low-density lipoprotein.

(WHO) proposed a unifying definition for the syndrome and decided to call it *metabolic syndrome*.^{1,12,13}

Prevalence and diagnosis of metabolic syndrome

The prevalence of metabolic syndrome depends on some factors such as gender, age, and ethnicity and ranges between 15% and 40% of the total world population, being more latent in Hispanics. This syndrome is present in 22–34% of the U.S. population; whereas in Mexico, this percentage increased from 28% to 40% between 1994 and 2000 and was about 42% from 2006 to 2012, being more often in women than men according to the National Health and Nutrition Survey (NHNS).^{11,14}

As this condition is a syndrome and not a disease, relatively simple biochemical and anthropometric parameters are required for its diagnosis. Table 1 shows the diagnostic criteria for metabolic syndrome proposed by the WHO, the National Cholesterol Education Program–Expert Panel on Detection, Adult Treatment Panel III (NCEP-ATP III), and the International Diabetes Federation (IDF).^{13,15,16}

The WHO considers IR as a needed component of metabolic syndrome, whereas the IDF considers AO as more relevant.⁹ The NCEP-ATP III selected three out of five parameters that generated controversy. Also, highlighting five parameters only (and no more) is highly questionable. However, the NCEP-ATP III is also highly accepted and has a great clinical use due to the routine nature of its parameters that can be measured in a medical consulting room. Therefore, this review took the parameters stated by the NCEP-ATP III as a reference to determine the factors involved in metabolic syndrome (AO, fasting blood sugar level, dyslipidemia, hypertriglyceridemia, low high-density lipoprotein [HDL], and AP).⁹

Abdominal obesity. Obesity is the accumulation of AT that increases the corporal weight. Adipocytes act as a dynamic tissue in response to nutritional adaptation and suffer

a misbalance that is characterized by an increase in their capacity to expand. Therefore, the plasticity of the AT is a key factor for understanding obesity.¹⁷ The existence of a dysfunctional metabolism in the organism, along with an increase in the size of the adipocytes in the waist and hip areas (i.e., AO), leads to a misbalance of the cytokines that decreases adiponectin and increases the release of leptin, IL-6, and TNF- α . This situation contributes significantly to the inflammatory state, IR, DM, dyslipidemia, arterial hypertension (AHT), and metabolic syndrome.^{17–19} Fat accumulation in the abdomen (android model) has increased during the past decades due to changes in lifestyle and diets.^{14,20–22}

Genetic predisposition, diet, lifestyle, and environmental factors are some of the causes of AO. These factors favor energetic misbalance, inflammation, and the increase in AT. AO is currently a public health problem due to the alarming increase in the number of people with this disease.²³

Mexico holds the first place at the global level in overweight and obesity, with 71.3% of its adults (people older than 20 years) suffering these conditions, that is, 48.6 million people. The prevalence of AO in women and men is 82.8% and 64.5%, respectively. It is lower in people aged between 20 and 29 years (53.3%) than in adults who are 40+ years (80%).¹⁴

Diabetes mellitus

Besides AO, DM (fasting blood sugar level higher than 100 mg/dL) also constitutes part of the set of diseases that are associated with metabolic syndrome. In fact, DM is currently the most relevant metabolic disorder as it affects almost all the organs of the body. This disease affects a high percentage of the productive population and therefore, the Health Sector considers it as a nosological problem that deserves priority attention.²⁴

DM is a set of biochemical, physiological, and anatomical abnormalities that are derived from a disturbance of glucose homeostasis and a deficiency in the secretion of insulin by

TABLE 1. BIOCHEMICAL AND ANTHROPOMETRIC PARAMETERS USED TO DIAGNOSE METABOLIC SYNDROME^b

<i>OMS criteria</i>	<i>NCEP-ATP III criteria</i>	<i>IDF criteria</i>
<p>The insulin resistance is identified by means of some of the following parameters:</p> <ol style="list-style-type: none"> 1. Type 2 diabetes. 2. Glucose intolerance: 126 mg/dL 2 h after a glucose charge of 140 and 200 mg/dL. 3. Impaired fasting glucose ≥ 110 mg/dL. 4. Insulin resistance. Glucose capture below the lowest quartile of the population. <p>And some of the following parameters:</p> <ol style="list-style-type: none"> 1. Abdominal obesity (BMI >30 kg/m² and/or a waist-hip ratio >0.9 and >0.85 for men and women, respectively) 2. Plasma triglycerides ≥ 150 mg/dL. HDL-C lower than 35 and 39 in men and women, respectively. 3. Arterial pressure $\geq 140/90$ mmHg. 4. Microalbuminuria (urinary albumin excretion rate ≥ 20 μg/min or an albumin-to-creatinine ratio ≥ 30 mg/g). 	<p>Three of the following parameters are required to diagnose metabolic syndrome:</p> <ol style="list-style-type: none"> 1. Abdominal obesity given by an increase in the waist (>102 cm in men and >88 cm in women^a). 2. Fasting glucose level ≥ 110 mg/dL. 3. Arterial pressure $\geq 130/85$ mmHg. 4. Triglycerides ≥ 150 mg/dL. 5. HDL-C <40 mg/mL in men and <50 mg/dL in women. 	<p>Abdominal obesity (considering the increase across waist circumference) ≥ 94 and ≥ 80 cm in European men and women, respectively, and with specific values for other ethnicities.</p> <p>Two or more of the following factors:</p> <ol style="list-style-type: none"> 1. Impaired fasting glucose ≥ 110 mg/dL or previous diagnosis of type 2 diabetes. 2. Triglycerides ≥ 150 mg/dL. 3. HDL-C lower than 40 and 50 in men and women, respectively. 4. Arterial pressure ≥ 130 mmHg (systolic)/≥ 85 mmHg (diastolic).

^aAbdominal circumference.

^bRefer to Ref. 9.

BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program—Expert Panel on Detection, Adult Treatment Panel III; WHO, World Health Organization.

beta-type cells in the pancreas. It is frequently associated with AO and other diseases that are associated with metabolic syndrome, triggering a set of difficulties in the long term that increase cardiovascular mortality and ischemic cardiomyopathy by three to four times.^{25,26}

DM can be classified into two groups: (1) The first (type 1 group) is frequently used to describe the appearance of the diabetes derived from the inability of the pancreas to produce enough insulin to catch all the glucose, and (2) the second (type 2 group) is mainly associated with IR.^{27,28}

Several researchers agree that the increase in abdominal fat and the deterioration of insulin signaling are the main responsible factors for type 2 diabetes. IR has been very related to the reduction in the metabolic capacity to return to its normal circulation, implying an abnormal biological answer to the body systems. This pathologic feature of the disease is a key factor of metabolic syndrome.^{3–5,29}

In Mexico, about 10% of the population suffer from DM and it is estimated that 90% of these cases are of type 2 diabetes, which is more frequent in older adults and obese people. Thus, this disease has become the main mortality reason, with 12% of the total deaths.³⁰

Data provided by the NHNS (2012) identified 6.4 million Mexican adults suffering diabetes, that is, 9.2% of the adults in the country who have already been diagnosed with diabetes. The prevalence of diabetes in 40–49 year-old people increased by 50% from 2000 to 2012—not counting diabetic people who are not aware about their condition.¹⁴

The WHO estimated that the number of people suffering diabetes worldwide in 1995 was 30 million and that this number increased up to 347 million in 2014. The same institution projected that 366 million people worldwide would suffer diabetes by 2030.^{31,32}

Arterial hypertension

AHT is a chronic and degenerative disease that is associated with metabolic syndrome and it is defined as a steady, high systemic AP. It is generally diagnosed by means of three separate measurements of elevated systolic and/or diastolic pressures (higher than 120 and 80 mmHg, respectively). The seventh report of the Joint National Committee for the Prevention, Detection, and Evaluation of AHT (JNC7) established new treatments for normal and prehypertension levels as well as two stages for AP (Table 2).^{33,34}

The JNC7 recommends keeping an AHT lower than 140/90 mmHg for most of the patients and lower than 130/80 mmHg for patients suffering DM or renal disease. Currently, AHT affects about 26.4% of the adult population and 60–70% of the people in their 70s. This disease is very prevalent in Mexico as, according to the NHNS, about 31.5% of the population older than 20 years suffer this condition, being more frequent in obese adults (42.3%) and diabetic adults (65.6%). Further, more than 50% of men and 60% of women older than 50 years suffer

TABLE 2. CLASSIFICATION OF THE ARTERIAL PRESSURE IN ADULTS (JNC7)^a

<i>Blood pressure classification</i>	<i>Systolic pressure (mmHg)</i>	<i>Diastolic pressure (mmHg)</i>
Normal blood pressure	≤ 120	≤ 80
Prehypertension	120–139	80–89
Stage 1 hypertension	140–159	90–99
Stage 2 hypertension	≥ 160	≥ 100

^aRefer to Ref. 34.

JNC7, Seventh Report of the Joint National Committee for the Prevention, Detection, and Evaluation of AHT.

AHT. The prevalence of AHT in Mexico increased from 19.7% to 31.5%, affecting one out of three adults.^{32,35}

Metabolic syndrome increases the harmful effects of the AHT on arteries by increasing their stiffness and intensifying any cardiovascular problem. Hence, the physiopathological association between metabolic syndrome and AHT leads to an increase in cardiovascular risks.¹²

AHT is an extremely frequent co-morbidity in diabetic people that affects 20–60% of the population suffering DM. The prevalence of hypertension in the diabetic population is 1.5–3 times higher than in nondiabetics, thus contributing to the development of chronic complications of the disease. Extensive epidemiological evidence indicates that diabetic people with hypertension have a significant increased risk of suffering cardiovascular diseases, renal insufficiency, and diabetic retinopathy.³⁴

Dyslipidemia (hypertriglyceridemia and cholesterolemia)

Dyslipidemias are considered an alteration in the lipid metabolism that is characterized by an excess of triglycerides, total cholesterol (hypercholesterolemia), both of them (hyperlipidemia), and/or a low content of HDL-cholesterol particles. These dyslipidemias are one of the factors of metabolic syndrome and emerge when the lipid metabolism gets affected by OA, DM, AHT, or others. The rise of visceral fat in the human body increases lipolysis speed, leading to a greater mobilization and an increase of the circulating free fatty acid levels.³⁶

Insulin regulates the abnormal lipolysis effect on AT and also the free fatty acid release. Thus, insulin inactivity leads, in general, to an increase in lipolysis with a negative effect on arteries. This generates a lot of complications, including endothelial dysfunction, inflammatory processes, stimulation of platelet aggregation, metalloproteinase expression, and thrombogenesis.^{37,38}

Genetics and environmental factors (diets rich in saturated fats and sedentarism) lead to an increase in the lipid content in blood. This triggers the accumulation of atheromatous plaques on the vascular endothelium, which are the prelude of organic consequences such as cardiovascular diseases and CVDs. In Mexico, the prevalence of dyslipidemia in women and men is 28.8% and 26.5%, respectively.¹⁴

Treatment and prevention of metabolic syndrome

Currently, there are several medicaments available to treat the disruptions that are associated with metabolic syndrome. These are chemically synthesized drugs that will have, in the long term, secondary and undesired effects such as lactic acidosis, metallic taste, and vitamin B₁₂ deficiency.^{3,5,39} There is then a new demand of new products based on medicinal plants for the treatment of diseases that are associated with metabolic syndrome, with SR being a potential alternative.⁴⁰

SR BERTONI: AN ALTERNATIVE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME

The genre *Stevia* has at least 110 identified species, and SR is particularly popular due to its sweetening capacity that

made it known as the *Sweet Herb of Paraguay*.⁶ The fame of the SR has increased due to its absence of toxicity, and it is considered an edible plant worldwide.⁷ SR is a herbaceous perennial plant that belongs to the *Asteraceae* family. It grows as a wild shrub reaching up to 65–80 height, has sessile leaves arranged oppositely, and is often asexually propagated (Fig. 2).⁶

Phytochemicals of SR

Currently, SR is commercially cultivated to extract its sweeteners. However, it contains other compounds (including phytochemicals) that provide beneficial properties to health.⁴¹ The compounds responsible for the sweetness of this plant were reported in 1931 when the French chemists, M. Bridel and R. Lavieille, isolated the steviol glycosides (Fig. 3) that provide its taste. These compounds were called stevioside and rebaudioside and are used by the food industry as sweeteners.⁷ Stevioside and rebaudioside A (the sweetest compound) represent 5–10% and 2–4% w/w (dry basis) of the leaves. There are also other minority glycosides such as rebaudiosides B, rebaudiosides C, rebaudiosides D, rebaudiosides E, rebaudiosides F, dulcoside A, rubusoside, and steviolbioside.^{42,43} Rebaudioside A is used by the food industry as a substitute for saccharose, whereas stevioside has therapeutic applications for the treatment of DM, obesity, caries prevention, and AP decrease.^{44–47}

Besides steviol glycosides, SR has more than 100 phytochemicals and other compounds with antioxidant and medicinal properties.⁴⁸ The leaves have a complex mixture of compounds, including diterpenes, labdabos, triterpenes,



FIG. 2. *Stevia rebaudiana* Bertoni. Perennial herbaceous plant belonging to the *Asteraceae* family, originating from the spontaneous flora in the semi-arid habitat of the mountainous slopes of Paraguay. Color images available online at www.liebertpub.com/jmf




FIG. 3. Chemical structure of the steviol molecule.

stigmasterol, tannins, ascorbic acid, alkaloids, steroids, saponins, flavonoids, β -carotene, chromium, cobalt, magnesium, iron, potassium, phosphorus, riboflavin, thiamine, tin, zinc, apigenin, austroinilina, avicularin, β -sitosterol, caffeic acid, campesterol, caryophyllene, centaureidin, chlorogenic acid, chlorophyll, kaempferol, luteolin, and quercetin.⁸

Biological effects of SR Bertoni

The extract from SR leaves is stable at 200°C, does not contain calories, does not ferment, does not generate dental plaque, is anti-caries, does not caramelize, and does not crystallize. Thus, the extract from SR leaves has multiple uses in several industries.^{45,49–54} SR has also several biological

properties, including antacid, cardiotoxic, anti-caries, anti-rotavirus, anti-bacterial, anti-hypertensive, anti-fungal, anti-inflammatory, anti-viral, anti-yeast, diuretic, antioxidants, hypotensive, antihyperlipidemic, and anticancer. Further, its antihyperlipidemic and insulinotropic effects contribute to the treatment of type 2 diabetes by stimulating the secretion of insulin by beta-type cells of the pancreas.^{7,32,42,55–57}

SR and AO

Diets with a high glycemic index and high sugar consumption induce a set of metabolic complications, including IR, hyper insulin, DM, HTA, and AO. Therefore, substituting sugars with calorie-free sweeteners is an efficient strategy.⁵⁸ In the past years, SR glycosides have become attractive substitutes for sugar. They are intense calorie-free sweeteners that are helpful to control the ingestion of calories in diet, reduce weight, do not have adverse effects when consumed, and reduce AO (which is associated with a set of diseases, including abnormal metabolism of lipids, hypertension, DM 2, and others).^{46,58,59} A study found that satiety levels of SR, aspartame, and saccharose were similar among each other. However, SR reduced the glucose and postprandial insulin levels.⁵⁸ Nowadays, SR glycosides are used by diverse countries to sweeten local tea, medicines, food, and diet drinks.⁶⁰

Diterpene glycosides are degraded to steviol by the intestinal flora of diverse animal species, including humans, which explains their benefits. Steviol is a molecule containing a hydrophobic ring and a negative charge in the carboxylic group. Unlike steviol, glycosides have a very limited absorption due to the monolayers of the Caco-2 cells.^{28,61,62}

Glycosides produce a maximum plasmatic concentration of 0.2 nM of steviol. It is completely absorbed by the large intestine and excreted by renal and biliary systems. After oral ingestion of glycosides, steviol is the main metabolite found in blood circulation and therefore, its metabolism in the liver has received special attention.^{42,63} Substituting sugars with non-nutritive sweeteners, such as steviol glycosides, can lead to a loss of 380 cal/day or 1 lb of body weight in 9–10 days.⁶¹ Table 3 summarizes some studies regarding the effects of the SR extracts on body-weight loss. Orally administered

TABLE 3. ANTI-OBESITY EFFECTS OF *STEVIA REBAUDIANA*

Model	Methodology	Results	References
Wistar rats	Oral treatment with 97% pure rebaudioside A (0, 25,000, 50,000, 75,000, and 100,000 ppm) for 4 weeks.	Rebaudioise A reduced the body weight of the rats, their biliary acids, and serum cholesterols.	64
Obese and diabetic mice	Oral treatment with isosteviol (20 mg/kg) during 9 weeks.	The isosteviol regulated the gene expression of beta-type cells, reduced triglycerides, and favored the body weight reduction of mice.	66
Streptozotocin-induced (55 mg/kg) diabetic Long-Evans rats (<i>Ratus norvegicus</i>)	Oral treatment with SR under a 2, 5, and 10 mg/kg dose for 21 days. The blood glucose level and body weight were measured at 0, 7, 14, and 21 days of starting the treatment.	The treatment had an antihyperglycemic effect and also reduced the body weight of the experimental rats.	5

SR, *Stevia rebaudiana*.

TABLE 4. HYPOGLYCEMIC AND ANTIHYPERGLYCEMIC EFFECTS OF *STEVIA REBAUDIANA*

<i>Model</i>	<i>Methodology</i>	<i>Results</i>	<i>References</i>
Nonobese diabetic GK rats	Oral treatment with stevioside in water (25 mg/kg) for 6 weeks testing the intra-arterial glucose tolerance.	The treatment had an antihyperglycemic effect and resulted in an increase in insulin.	74
Healthy male Wistar rats	Oral treatment with extract from SR leaves (20 mg/kg/day) and stevioside (5.5 mg/kg/day) during 15 days.	The extract reduced glycemia and hepatic gluconeogenesis. This is not the case for the stevioside, which did not have any effect on these parameters.	71
Nonobese diabetic GK rats	Oral treatment with stevioside in water (30 mg/kg) coupled with a soy-based diet for 3 weeks. The intra-arterial glucose tolerance was tested.	There was an antihyperglycemic effect, a reduction in glucagon, and an increase in insulin.	76
Streptozotocin-induced (55 mg/kg) diabetic rats	Oral treatment with aqueous extract of powdered SR leaves under doses of 150, 200, and 250 mg/kg for 3 weeks.	The aqueous extract had a hypoglycemic effect. Further, the 250 mg/kg dose achieved a decrease in the body weight of the rats.	73
Alloxan-induced diabetic Wistar rats	Oral treatment with the aqueous, methanolic, and etheric extracts during 28 days.	The treatment reduced the blood glucose.	68
Alloxan-induced diabetic Long-Evans rats	Oral treatment with five alcoholic extracts from SR leaves under a unique dose of 150 mg per kg of body weight of hyperglycemic rats.	There was a favorable effect on the reduction in the intensity of the hyperglycemia and also an improvement in the glucose tolerance activity.	72
Alloxan-induced (180 mg/kg) albino diabetic Wistar rats	Oral treatment with medium-polar extract from SR leaves under doses of 200 and 400 mg/kg for 10 days.	The treatment significantly reduced blood glucose levels without generating conditions for hypoglycemia.	69
Streptozotocin-induced (60 mg/kg) diabetic Wistar rats	During a month, rats had a dairy diet consisting of powdered <i>Stevia</i> leaves and polyphenols and fiber (both taken from SR).	There was a reduction in blood glucose and an increase in insulin.	75
Alloxan-induced (150 mg/kg) diabetic rats	Oral treatment with extract from SR leaves under a 250 mg/kg dose during 28 days.	There was a significant antioxidant effect and a decrease in the hyperglycemic levels.	67
Alloxan-induced (150 mg/kg) diabetic mice	The methanolic extract from SR leaves was administered under a 300 mg/kg dose for 21 days. After that, the animals were sacrificed and their blood and organs were used for detecting biochemical and histopathologic changes.	The treatment significantly decreased the blood glucose level and also the high hepatic glycogen content.	70
Patients suffering type 2 diabetes	A standard meal with 1 g of stevioidise was administered. The blood glucose level was measured 240 min later.	The treatment reduced the postprandial blood glucose. This indicates a beneficial effect on the metabolism of glucose.	40
Male diabetic Wistar rats induced with nicotinamide (120 mg/kg) and streptozotocin (65 mg/kg)	Acute treatment: Oral treatment with aqueous extract from SR leaves (Morita II variety) under a unique 10 mg/kg dose. Chronic treatment: Oral treatment with croquettes containing the SR extract under a 500 mg/kg dose.	The treatment had a low glycemic index. Neither the acute nor the chronic treatments had any effect on the blood sugar levels of diabetic animals. This indicated that both treatments are suitable as sweeteners.	28

GK, Goto-Kakizaki.

rebaudiodise A reduced the body weight, biliary acids, and serum cholesterol of rats.⁶⁴ Healthy patients achieved a maximum plasma concentration after 8 or 12 h of being administered (via the oral route) with rebaudiodise A, and most of the steviol (62% of the dose) was found as conjugated glucuronides. This indicated that, besides Phase I of metabolism, steviol also goes through Phase II, and most of the steviol is conjugated as glucuronide before being eliminated in the urine.⁶⁵ Isosteviol (compound of the metabolism of stevioside) improved the lipid profile and regulated the expression of beta-type cells by including regulating factors for

insulin transcription, reducing the triglyceride content in plasma, and favoring body-weight loss in diabetic mice.⁶⁶ Extracts from SR, administrated via the oral route, showed a body-weight reduction in diabetic rats.⁵

SR Bertoni and DM

Diterpene glycosides in SR extracts act as an intense and a calorie-free sweetener and, if they reduce the sugar levels, they will have hypoglycemic effects. On the other hand, if they avoid the rise of the glucose level induced by some

TABLE 5. ANTIHYPERTENSIVE AND HYPOTENSOR EFFECT OF *STEVIA REBAUDIANA*

<i>Model</i>	<i>Methodology</i>	<i>Results</i>	<i>References</i>
Healthy male Wistar rats	Oral treatment with aqueous extract from SR leaves during 20, 40, and 60 days.	The extract shows renal vasodilation, hypotension, diuresis, and natriuresis after 60 days of starting the treatment.	78
Wistar rats	Infusion of steviols under doses of 0.5, 1, and 3 mg/kg.	There were no significant changes in the AP. However, there was a significant increase in the sodium excretion and water transportation through renal tubules under doses of 1 and 3 mg.	79
SHR male rats	Intravenous treatment with stevioside under doses of 50, 100, and 200 mg/kg.	The treatment reduced the AP efficiently. The 200 mg/kg dose had the highest hypotensor effect.	33
Patients suffering arterial hypertension	1-year oral treatment with capsules containing 250 mg of stevioside.	After 3 months, the treatment significantly reduced the systolic and diastolic APs. There were no adverse effects.	81
SHR male rats	Intraperitoneal treatment with 95% pure steviol under a 25 mg/kg dose.	The stevioside had a hypertensive effect that caused a vasorelaxation by inhibiting the Ca ²⁺ in blood vessels.	82
Diabetic GK rats	Treatment with 99.6% pure stevioside under a daily dose of 0.025 g/kg for 6 weeks.	There was a positive effect as the treatment had an antidiabetic effect and reduced arterial pressure. These effects can also have potential therapeutic effects for the treatment of metabolic syndrome.	74
Patients suffering mild essential hypertension	2-year oral treatment with capsules containing 500 mg of steviosides. This treatment was given to people (20–75 years old) who suffered mild essential hypertension.	There was a decrease in the systolic and diastolic pressures compared with the placebo.	80
Isolated aortic rings of Wistar rats contracted with vasopressin.	Treatment with isosteviol under concentrations of 10 ⁻⁸ and 10 ⁻⁵ M.	Isosteviol reduced the contraction of the isolated aortic rings. Better results were achieved under a concentration of 10 ⁻⁵ M.	83
Patients suffering mild essential hypertension	Oral treatment with stevioside under doses of 3.75, 7.5, and 15 mg/kg during 11 weeks.	No hypotensor effect was found. However, it did not have any toxicity during the period of the treatment.	84
Aortic cells of the smooth muscle of male Sprague-Dawley rats	Cells were incubated with steviol (1–100 μM) during 30 minutes.	Isosteviol-incubated cells significantly inhibited angiotensin-II.	85

AP, arterial pressure; SHR, spontaneously hypertensive; M, Mol.

TABLE 6. ANTIHYPERLIPIDEMIC EFFECTS OF *STEVIA REBAUDIANA*

<i>Model</i>	<i>Methodology</i>	<i>Results</i>	<i>References</i>
Alloxan-induced (150 mg/kg) diabetic rats	The methanolic extract from SR leaves was daily administered under a 300 mg/kg dose during 21 days.	A significant antihyperlipidemic effect was observed. The lipidic parameters were reduced to their normal levels during the treatment.	70
Alloxan-induced (110 mg/kg) diabetic Long-Evans rats	Oral treatment with five alcoholic extracts from SR leaves under a unique dose of 150 mg per kg of body weight of hyperglycemic rats.	There was a significant and favorable effect on the improvement of the antihyperlipidemic activity.	72
Alloxan-induced (200 mg/kg) diabetic Long-Evans rats	Oral treatment with titanium oxide-based nanomatrices and ethanolic extracts from <i>Stevia</i> (TiO ₂ -SrB).	There was a significant decrease in the glucose concentration from the first 24 h until 30 days after the administration. The concentrations of insulin, hemoglobin, glycosylase, cholesterol, and triglycerides returned to their normal levels.	86
20 women suffering hypercholesterolemia	Oral treatment with aqueous extract from SR (20 mL) during 1 month.	The treatment resulted in a decrease in the levels of cholesterol, triglycerides, and low-density lipoproteins.	87

agent (such as adrenaline, glucagon, alloxan, and glucose charge), they will have antihyperglycemic effects.²⁸ Some studies indicate that SR can help to reduce blood glucose levels in diverse animal models such as healthy mice, diabetic mice, alloxan or streptozotocin-induced mice, or mice supplied with aqueous or alcoholic extracts from SR in an acute or chronic way during 10–48 days (Table 4). Orally administered SR extract showed an antihyperglycemic effect,⁶⁷ a decrease of the blood glucose levels in diabetic rats under a time-dependent effect,^{68,69} and a reduction of the hepatic gluconeogenesis of diabetes-induced mice.^{70,71} SR also improved the glucose tolerance activity,⁷² and the powder of its leaves had a hypoglycemic effect on diabetic rats.⁷³ The induction of the genes involved in glycolysis may be responsible for the increase in insulin secretion caused by the consumption of the stevioside and the suppression of glucagon in α -type cells of the pancreas.^{63,74} Moreover, this glycoside reduces the blood glucose level as it modulates and inhibits the enzymes that metabolize glucose in the small intestine and it propitiates a better use of the glucose by periphery tissues and muscles of diabetic rats.^{63,74–76} In a study, steviosides (20 mg/kg body weight) were administered to 12 people suffering DM 2, resulting in a decrease in the plasmatic glucose concentration by decreasing the activity of the pyruvate carboxylase and the phosphoenolpyruvate carboxikinase (PEPCK). This also reduced postprandial glucose levels in the blood by about 18%.⁶³ Some studies indicate that the SR-based treatment on healthy volunteers increased their glucose tolerance and reduced their concentrations of plasmatic and postprandial glucoses.^{40,77}

SR Bertoni and AHT

Diverse studies on animal models and hypertensive patients report that SR extracts and pure isolated stevioside have a relevant effect on the cardiovascular system (Table 5). In an experimental model, extracts from SR leaves were orally administered to healthy rats in a chronicle way. Results indicated a vasodilating action, diuresis, and natriuresis 60 days later.⁷⁸ The infusion of isolated steviol may affect the water transport through renal tubules, leading to a decrease in the blood that circulates in the cardiovascular system caused by increasing the amount of urine and sodium excreted by the body.⁷⁹ The increase of the stevioside-induced plasmatic renal flow reduces the vascular resistance and is associated with the vasodilatation of the vessels of afferent and efferent arterioles by means of the inhibition and influx of intracellular calcium and the release of a vasodilator prostaglandin.⁷⁹ A study indicates that a 200 mg/kg dose of isolated stevioside could effectively reduce the AP of spontaneously hypertensive (SHR) male rats without affecting their heart rate or their serum catecholamines levels.³³ Diabetic Goto-Kakizaki rats were administered with a chronic dose of 0.025 g/kg of stevioside during 6 weeks, and their AP was reduced during that period.⁷⁴ Oral and chronic treatment (2 years) with steviosides (500 mg) on hypertensive patients reduced their AP compared with placebos, and

also the systolic and diastolic APs from 150 to 140 mmHg and from 95 to 89 mmHg, respectively.⁸⁰

In another study, 250 mg of steviosides was administered in hypertensive patients during 1 year. Results indicate that their systolic and diastolic APs decreased after 3 months of starting the treatment without any negative effect on the biochemical parameters.⁸¹ The stevioside, administered via the intraperitoneal route in SHR rats, had an antihypertensive effect that caused vasodilation by inhibiting the Ca^{2+} flow in blood vessels.⁸² Other *in vitro* studies concluded that the isosteviol, derived from the stevioside, inhibited Angiotensin-II and cell proliferation in the smooth muscle of rats. Isosteviol also reduced the vasopressin-induced contraction in isolated aortic rings by means of opening the KATP and SKCa channels.^{83,85}

SR Bertoni and dyslipidemia

Table 6 summarizes some studies regarding the anti-hyperlipidemic effect of SR. Alloxan-induced diabetic animals were administered, via the oral route, with aqueous and alcoholic extracts from SR under a chronic dose for 21 days,⁷⁰ and under an acute dose of 150 mg/kg.⁷² Both treatments had a significant antihyperlipidemic effect. An oral and chronic treatment consisting of titanium oxide-based nanomatrices and SR extracts significantly decreased cholesterol and triglycerides.⁸⁶ Studies on humans indicate that the consumption of SR extracts increased the level of HDL and reduced the levels of cholesterol, triglycerides, and low-density lipoproteins significantly.⁸⁷

CONCLUSIONS

Studies on SR demonstrate that, besides being suitable as a sweetener, the aqueous and alcoholic extracts of this plant, as well as its steviol, are also a pharmacological alternative. In other words, these compounds have the required therapeutic potential for naturally treating endocrine diseases (such as obesity, diabetes, hypertension, and dyslipidemia) that are relevant in the current context. These diseases are associated with metabolic syndrome, which is considered a public health problem due to its current prevalence. Besides steviol glycosides, SR contains several phytochemicals, including phenols and flavonoids. More research is needed to determine their effects on the already known SR-based treatments, as well as their diverse mechanisms of action.

AUTHOR DISCLOSURE STATEMENT

No competing financial interests exist.

REFERENCES

1. Pineda CA: Metabolic syndrome: Definition, history, criteria. *Colomb Méd* 2008;39:96–106.
2. Ando K, Fujita T: Metabolic syndrome and oxidative stress. *Free Radic Biol Med* 2009;47:213–218.
3. Giner LEM, Castillo GE: Phytotherapy and diabetes. [In Spanish]. *Fitoterapia* 2003;3:113–122.

4. Chang JC, Wu MC, Liu IM, Cheng JT: Increase of insulin sensitivity by stevioside in fructose-rich chowfed rats. *Horm Metab Res* 2005;37:610–616.
5. Dutta PK, Razu MMT, Alam MK, Awal MA, Mostofa M: Comparative efficacy of aqueous extract of Stevia (*S. rebaudiana* Bertoni) leaves and metformin hydrochloride (Comet[®]) in streptozotocin induced diabetes mellitus in rats. *Int J Biol Res* 2010; 2:17–22.
6. Jarma AJO, Enrique MCC, Cleves LJA: Nutritional and metabolic aspects of *S. rebaudiana* (Bertoni). [In Spanish]. *Rev Agron Colomb* 2010;38:199–208.
7. González-Moralejo SA: An approach to understand a potential natural sweetener, *S. rebaudiana* Bertoni: production, consumption, and potential demand. [In Spanish]. *Agroalimentaria* 2011;17:57–69.
8. Bakar S, Rahman MMR, Hossain MA, Rashid MA: Phytochemical screening and comparative antimicrobial potential of different extracts of *Stevia rebaudiana* Bertoni leaves. *Asian Pac J Trop Dis* 2014;4:275–280.
9. Contreras-Leal EA, Santiago-García J: SM and its impact on cardiovascular diseases. [In Spanish]. *Rev Biomed* 2011;22: 103–111.
10. Aranda-Gonzalez I, Moguel-Ordoñez Y, Betancur-Ancona D: Rapid HPLC method for determination of rebaudioside D in leaves of *Stevia rebaudiana* Bertoni grown in the Southeast of México. *Am J Anal Chem* 2014;5:813–819.
11. Galván-Meléndez MF, Calderón-Salinas JV, Intriago-Ortega MP, Torres-Castorena A: Oxidative stress in patients with different clinical expression of metabolic syndrome. *Med Int Méx* 2014; 30:651–659.
12. Cordero FA, Moreno AJ, Alegría EE: Hypertension and metabolic syndrome. *Hipertensión* 2006;23:19–27.
13. Gogia A, Agarwa PK: Metabolic syndrome. *Indian J Med Sci* 2006;60:72–81.
14. National Survey of Health and Nutrition 2012. National Results. National Institute of Public Health [In Spanish], México, 2012.
15. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. *Lancet* 2005;365:1415–1428.
16. Coniglio RI, Ferraris R, Prieto A, Vásquez LA, Garro S, Trípodí MA, *et al.*: Relationship between the metabolic syndrome and the insulin resistance in adults with type 2 diabetes risk. *Acta Bioquím Clín Latinoam* 2013;47:25–35.
17. Schnell M, Domínguez Z, Carrera C: Genetic, clinical and pathophysiological aspects of metabolic syndrome. [In Spanish]. *An Venez Nutr* 2007;20:92–98.
18. Grundy SM, Cleeman JI, Merz NB, Brewer B, Clark LT, Hunnigake DB, *et al.*: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *J Am Coll Cardiol* 2004;44:720–732.
19. Vitarius JA: The metabolic syndrome and cardiovascular disease. *Mt Sinai J Med* 2005;72:257–260.
20. Scarsella C, Després J: Treatment of obesity: the need to target attention on high-risk patients characterized. [In Spanish]. *Cad Saúde Pública* 2003;19:S7–S19.
21. Almeida RT, Guimarães MM, Araújo TM: Abdominal obesity and cardiovascular risk: performance of anthropometric indexes in women. [In Spanish]. *Arq Bras Cardiol* 2009;92:362–367.
22. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco J: Prevalence of obesity in Mexican adults. [In Spanish], 2000–2012. *Salud Pub Méx* 2013;55:151–160.
23. Gamal AM, Sabrin RM, Ehab SE, Riham SE: Natural anti-obesity agents. *Bull Fac Pharm* 2014;52:269–284.
24. Aguilar CG: Determining the hypoglycemic and *phoradendron tommtom* (dc) engelm activities on a model consisting of diabetic rats for experimentation (Master thesis). [In Spanish]. Monterrey, Nuevo León. Universidad Autónoma de Nuevo León, 2001.
25. González SE, Pascual CI, Laclaustra GM, Casasnovas JA: Metabolic syndrome and diabetics. [In Spanish]. *Rev Esp Cardiol Supl* 2005;5:30D–37D.
26. Burgos PR, Joaquim C, Puiggrós LC, Chicharro SLL: Chronic DM type 2. [In Spanish]. *Nutr Hosp* 2010;3:35–45.
27. Mohd-Radzman NH, Ismail WIW, Adam Z, Jaapar SS, Adam A: Potential roles of *S. rebaudiana* Bertoni in abrogating insulin resistance and diabetes: A review. *Evid Based Complement Alternat Med* 2013;2013:718049.
28. Aranda-González I, Barbosa ME, Toraya-Avilés R, Segura-Campos M, Moguel-Ordoñez Y, Betancur-Ancona D: Safety assessment of *Stevia rebaudiana* Bertoni grown in southeastern Mexico as food sweetener. [In Spanish]. *Nutr Hosp* 2014;30:594–601.
29. Cardoso VN, Barbosa MF, Muramoto E, Mesquita CH, Almeida MA: Pharmacokinetic studies of 131I—Stevioside and its metabolites. *Nucl Med Biol* 1996;23:97–100.
30. Esquivel-Gutiérrez ER, Noriega-Cisneros R, Bello-González MA, Saavedra-Molina A, Salgado-Garciglia AR: Plants with anti-diabetics and antihypertensive properties used in the traditional Mexican medicine. [In Spanish]. *Biológicas* 2012;14:45–52.
31. World Health Organization. Obesity and Overweight. WHO, Geneva, 2008. www.who.int/dietphysicalactivity/publications/facts/obesity/en (last accessed August 10, 2016).
32. Betancur-Ancona D, Segura-Campos M, eds. *Stevia rebaudiana: Chemical Composition, Uses and Health Promoting Aspects*. New York: Nova Science Publisher, 2015, pp. 1–21.
33. Chan P, De-Yi X, Ju-Chi L, Yi-Jen C, Tomlimson B, Wen-Pin H, *et al.*: The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. *Life Sci* 1998; 63:1679–1684.
34. Cranwell-Bruce LA: Antihypertensives. *Medsurg Nurs* 2008;17: 337–341.
35. Chobanian AV, Bakris GL, Black HR, *et al.*: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. *JAMA* 2003;289:2560–2572.
36. Fonseca VA: The metabolic syndrome, hyperlipidemia, and insulin resistance. *Clin Cornerstone* 2005;7:61–65.
37. Van-Gaal LF, Mertens IL, De-block CE: Mechanisms linking obesity with cardiovascular disease. *Nature* 2006;444:875–880.
38. Bastarrachea RA, López-Alvarenga J, Bolano-García VE, Téllez-Mendoza J, Laviada-Molina H: Macrophages, inflammation, adipose tissue, obesity and insulin resistance. [In Spanish]. *Gac Méd Méx* 2007;143:505–512.
39. Dineshkumar B, Analava M, Manjunatha M: Studies on the anti-diabetic and hypolipidemic potentials of mangiferin (Xanthone Glucoside) in streptozotocin-induced Type 1 and Type 2 diabetic model rats. *Int J Adv Pharm Sci* 2010;1:75–85.
40. Gregersen S, Jeppesen PB, Holst JJ, Hermansen K: Anti-hyperglycemic effects of Stevioside in type 2 diabetic subjects. *Metabolism* 2004;53:73–76.
41. Atteh J, Onagbesan O, Tona K, Buyse JA, Decuyper EB, Geuns J: Potential use of *Stevia rebaudiana* in animal feeds. *Arch Zootec* 2011;60:133–136.

42. Goyal SK, Samsher, Goyal RK: Stevia (*S. rebaudiana*) a bio-sweetener: A review. *Int J Food Sci Nut* 2010;61:1–10.
43. Ashok KYS, Singh D, Dhyan Ahuj PS: A review on the improvement of *S. rebaudiana* [*S. rebaudiana* (Bertoni)]. *Can J Plant Sci* 2011;91:1–27.
44. Barriocanal L, Palacios M, Benitez G, Benitez S, Jiménez N, Rojas V: Apparent lack of pharmacological effect of steviol glycosides used as sweetener in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics. *Regul Toxicol Pharmacol* 2008;51:37–41.
45. Das K, Dang R, Gupta N: Comparative antimicrobial potential of different extracts of leaves of *S. rebaudiana* Bert. *Int J Nat Eng Sci* 2009;3:65–68.
46. Abou-Arab AE, Abou-Arab AA, Abu-Salem MF: Physicochemical assessment of natural sweeteners steviol glycosides produced from *S. rebaudiana* Bertoni plant. *Afr J Food Sci* 2010;4:269–281.
47. Preethi D, Sridhar TM, Josthna P, Naidu CV: Studies on antibacterial activity, phytochemical analysis of *S. rebaudiana* (Bert.)—An important calorie free biosweetener. *J Ecobiotech* 2011;3:05–10.
48. Jeppesen PB, Gregersen S, Poulsen CR: Steviol acts directly on pancreatic beta cells to secrete insulin: Actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K⁺-channel activity. *Metabolism* 2000;49:208–214.
49. Sah N, Khan M, Vohora SB: Antimicrobial activity of some medicinal plants extracts on *Escherichia coli*, *Salmonella paratyphi* and *Shigella dysenteriae*. *Fitoterapia* 1991;62:221–228.
50. Boeckh EM: Pharmacological trial of a concentrated crude extract of *S. rebaudiana* Bertoni in healthy volunteers. *Arquivos Biol Technol* 1992;35:299–314.
51. Tomita T, Sato N, Arai T, Shiraiishi H, Sato M, Takeuchi M, Kamio Y: Bactericidal activity of a fermented hot-water extract from *S. rebaudiana* Bertoni and other food-borne pathogenic bacteria. *Microbiol Immunol* 1997;41:1005–1009.
52. Melis A: Photosystem-II damage and repair cycle in chloroplasts: What modulates the rate of photodamage *in vivo*. *Trends Plant Sci* 1999;4:130–135.
53. Adebolu SA: Antimicrobial activity of leaf extracts of *Ocimum gratissimum* on selected diarrhoea causing bacteria in south-western Nigeria. *Afr J Biotechnol* 2005;4:682–684.
54. Debnath M: Clonal propagation and antimicrobial activity of an endemic medicinal plant *S. rebaudiana*. *J Med Plant Res* 2008;2: 045–051.
55. Galeano OV, González RS, and Velázquez LJ: Analysis of situation of the cluster of Stevia in Paraguay. Present, prospects and challenges for development. *Iberoamerican Journal of Industrial Engineering* 2010;1:2–25.
56. Orozco JA, Espitia CM, Fischer G: Steviol glycoside synthesis in Stevia (*Stevia rebaudiana* Bert). [In Spanish]. *Acta Biol Colomb* 2010;15:263–267.
57. Singh S, Garg V, Yadav D, Beg MN, Sharma N: *In vitro* anti-oxidative and antibacterial activities of various parts of *S. rebaudiana* (Bertoni). *Int J Pharm Pharm Sci* 2012;4:468–473.
58. Majchrzak D, Ipsen A, Koenig J: Sucrose-replacement by rebaudioside A in a model beverage. *J Food Sci Technol* 2015;52: 6031–6036.
59. European Food Safety Authority (EFSA). Scientific opinion on the safety of steviol glycosides for the proposed uses as a food additive. *EFSA J* 2010;8:1537.
60. Lemus-Mondaca R, Vega-Galvez A, Zura-Bravo L, Ah-Hen K: *Stevia rebaudiana* Bertoni, source of a high-potency natural sweetener: A comprehensive review on the biochemical, nutritional and functional aspects. *Food Chem* 2012;132:1128–1132.
61. Gupta R, Yadav V, Rastogi M: A review on importance of natural sweetener, a zero calorie plant-Stevia-having medicinal and commercial importance. *Int J Food Nutr Sci* 2014;3:89–94.
62. Salvador-Reyes R, Sotelo-Herrera M, Paucar-Menacho L: Study of Stevia (*S. rebaudiana* Bertoni) as a natural sweetener and its use in benefit of the health. *Sci Agropecu* 2014;5:157–163.
63. Marcinek K, Krejpcio Z: *Stevia rebaudiana* Bertoni: Health promoting properties and therapeutic application. *J Verbr Lebensm* 2016;11:3–8.
64. Curry LL, Roberts A: Subchronic toxicity of rebaudioside A. *Food Chem Toxicol* 2008;46:S11–S20.
65. Wheeler A, Boileau AC, Winkler PC, Compton JC, Prakash I, Jiang X, Mandarino DA: Pharmacokinetics of rebaudioside A and steviol glycoside after single oral doses in healthy men. *Food Chem Toxicol* 2008;46:S54–S60.
66. Nordentoft I, Jeppesen PB, Hong J, Abudula R, Hermansen K: Isoesteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KKAY mouse. *Diabetes Obes Metab* 2008; 10:939–949.
67. Sharma R, Rajesh Y, Elangvam M: Study of effect of *S. rebaudiana* Bertoni on oxidative stress in type-2 diabetic rat models. *Biomed Aging Pathol* 2012;2:126–131.
68. Kujur RS, Singh V, Ram M, Yadava HH, Singh KK, Kumari S, Roy BK: Antidiabetic activity and phytochemical screening of crude extract of *Stevia rebaudiana* in alloxan-induced diabetis rats. *J Pharmacogn* 2010;2:27–32.
69. Mishra N: An Analysis of antidiabetic activity of *S. rebaudiana* extract on diabetic patient. *J Nat Sci Res* 2011;1:1–9.
70. Singh S, Garg V, Yadav D: Antihyperglycemic and antioxidative ability of *S. rebaudiana* (Bertoni) leaves in diabetes induced mice. *Int J Pharm Pharm Sci* 2013;5:297–302.
71. Ferreira E, Rocha F, Duarte M, Alves W, De-Araujo L, Bazotte R: Comparative effects of *S. rebaudiana* leaves and steviol glycoside on glycaemia and hepatic gluconeogenesis. *Plant Med* 2006;72:691–696.
72. Hossain MS, Alam MB, Asadujjaman M, Islam MM, Rahman MA, Islam MA, Islam A: Antihyperglycemic and antihyperlipidemic effects of different fractions of *S. rebaudiana* leaves in alloxan induced diabetis rats. *Int J Pharm Sci Res* 2011;2:1722–1729.
73. Sumon MH, Mostofa M, Jahan MS, Kayesh MEH, Haque MA: Comparative efficacy of powdered form of Stevia (*S. rebaudiana* Bertoni) leaves and glimepiride in induced diabetic rats. *Bangl J Vet Med* 2008;6:211–215.
74. Jeppesen PBS, Gregersen SED, Rolfsen M, Jepsen M, Colombo A, Agger J, *et al.*: Antihyperglycemic and blood pressure-reducing effects of Steviol glycoside in the diabetic Goto-Kakizaki rat. *Metabolism* 2003;52:372–378.
75. Shivanna N, Naika M, Khanum F, Kaul VK: Antioxidant, anti-diabetic and renal protective properties of *S. rebaudiana*. *J Diabetes Complications* 2013;27:103–113.
76. Jeppesen PB, Dyrskog SE, Agger A, Gregersen S, Colombo M, Xiao J, *et al.*: Can steviol glycoside in combination with a soy-based dietary supplement be a new useful treatment of type 2 diabetes An *in vivo* study in the diabetic Goto-Kakizaki rat. *Rev Diabet Stud* 2006;3:189–199.
77. Curi R, Alvarez M, Bazotte RB: Effect of *S. rebaudiana* on glucose tolerance in normal adult humans. *Braz J Med Biol Res* 1986;19:771–774.

78. Melis MS: Chronic administration of aqueous extract of *Stevia rebaudiana* in rats: Renal effects. *J Ethnopharmacol* 1995;47:129–134.
79. Melis MS: A crude extract of *Stevia rebaudiana* increases the renal plasma flow of normal and hypertensive rats. *Braz J Med Biol Res* 1996;29:669–675.
80. Hsieh MH, Chan P, Sue YM, Liu JC, Liang TH, Huang TY, *et al.*: Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: A two-year, randomized, placebo-controlled study. *Clin Ther* 2003;25:2797–2808.
81. Chan P, Tomlinson B, Chen Y, Liu J, Hsieh H, Cheng J: A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. *Clin Pharmacol* 2000;50:215–220.
82. Lee C, Wong K, Liu J, Chen Y, Cheng J, Chan P: Inhibitory effect of stevioside on calcium influx to produce antihypertension. *Planta Med* 2001;67:196–799.
83. Wong K, Chan P, Yang H, Hsu F, Liu I, Cheng Y, Cheng J: Isosteviol acts on potassium channels to relax isolated aortic strips of Wistar rat. *Life Sci* 2004;74:2379–2387.
84. Ferri LAF, Alves-Do-Prado W, Yamada S, Gazola S, Batista MR, Bazzote RB: Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. *Phytother Res* 2006;20:732–736.
85. Wong K, Lin J, Liu J, Yang H, Kao P, Chen C, *et al.*: Anti-proliferative effect of isosteviol on angiotensin-II-treated rat aortic smooth muscle cells. *Pharmacology* 2006;76:163–169.
86. Díaz A, Villegas O, Lino AC, Treviño S, Carmona-Gutiérrez G, González-Coronel MA *et al.*: Hypoglycemic and antihyperlipidemic activity of TiO₂ nanostructured-conjugated *Stevia rebaudiana* Bertoni in a model of diabetes mellitus in rats. *Rev Mex Cienc Farm* 2013;44:36–42.
87. Sharma N, Mogra R: Effect of Stevia extract intervention on lipid profile. *Ethno Med* 2009;3:137–140.